Dr. Reddy's agrees to sell cancer drug HLX15, a biosimilar, in 43 countries, including the U.S., under a deal with Henlius.

Dr. Reddy's Laboratories has entered into a licensing agreement with Shanghai Henlius Biotech to commercialize HLX15, a biosimilar of daratumumab used for treating multiple myeloma, in 43 countries including the U.S. and Europe. Henlius will handle development, manufacturing, and supply, with potential payments up to $131.6 million. The deal aims to expand access to this cancer treatment in these markets.

1 month ago
6 Articles